April 9, 2021

Regina LaBelle
Director
Office of National Drug Control Policy
Executive Office of the President
Washington, D.C. 20503

Dear Director LaBelle:

The Alliance for Connected Care applauds the Office of National Drug Control Policy (ONDCP) for including a commitment to move forward with the telemedicine special registration for the prescribing of controlled substances this year as part of its First-Year Drug Policy Priorities.¹ As you know, the promulgation of this rule has been a patient and Congressional priority for many years.

Special registration for telemedicine was originally called for by Congress in the Ryan Haight Act of 2008. The Act directed the U.S. Drug Enforcement Administration (DEA) to create a special registration through which telemedicine providers would be exempted from the in-person requirement for prescribing of controlled substances. In response to concerns about the ongoing and escalating opioid epidemic, the SUPPORT for Patients and Communities Act, signed into law on October 24, 2018, included a provision requiring the Attorney General, in consultation with the Secretary of Health and Human Services, to within one year promulgate final regulations related to a Special Registration for Telemedicine. As you know, it has now been more than two full years since the SUPPORT Act was signed into law without appreciable progress from the DEA in moving forward a rulemaking process to implement this key telemedicine provision.

The Alliance for Connected Care is dedicated to improving access to care through the reduction of policy, legal and regulatory barriers to the adoption of telemedicine and remote patient monitoring. Our members are leading health care and technology companies from across the spectrum, representing health systems, health payers, and technology innovators. The Alliance works in partnership with an Advisory Board of more than 30 patient and provider groups, including many types of clinician specialty and patient advocacy groups who wish to better utilize the opportunities created by telehealth. The Alliance previously led a letter on this issue last fall urging DEA to immediately move forward with the telemedicine special registration process required by federal law. That letter, signed by over 80 organizations, is included in an appendix below for reference.

¹ “In the first year, the Biden-Harris Administration will work through ONDCP to coordinate with other White House components and the interagency to:

Publish final rules this year regarding telemedicine special registration and methadone treatment vans;”

We are pleased to hear this statement of priority from the Biden Administration and we urge the DEA to immediately take action to move forward on this important priority. The creation of a special registration process is needed so that telehealth providers can better reach patients struggling with substance abuse issues.

The urgency of this issue has never been greater – we are in the midst of a national public health crisis affecting everything from everyday life to employment, health care, and social factors.

The Alliance for Connected Care eagerly awaits forward movement from the DEA to facilitate the telemedicine special registration process required by federal law that will allow for the prescribing of medication assisted treatment to patients through telemedicine technology by appropriate SAMHSA waivered clinicians as well as Community Mental Health Centers, addiction treatment, and other appropriate facilities.

We look forward to working with you on this important matter.

Sincerely,

Krista Drobac
Executive Director

Attachment: October 26, 2020 Group Letter to the Drug Enforcement Administration (DEA)
October 26, 2020

The Honorable Timothy Shea
Acting Administrator
Drug Enforcement Administration (DEA)
Lincoln Place-West, 700 Army Navy Drive
Arlington, VA 22202

Dear Administrator Shea:

The undersigned organizations write to encourage the Drug Enforcement Administration (DEA) to expedite and complete its efforts to implement a telemedicine special registration process enabling providers to safely prescribe controlled substances remotely. Our experience during COVID-19 has demonstrated the value of increased access to telemedicine to enable all qualified providers, including Community Mental Health Centers and addiction treatment facilities, to prescribe Medication Assisted Treatment (MAT) to patients with Opioid Use Disorder (OUD).

On October 24, 2018, President Donald J. Trump signed into law the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act (P.L. 115-271). Section 3232 of the Act amends the Controlled Substance Act (CSA) Section 311(h)(2) to require that no later than one year after enactment, the Attorney General, in consultation with the Secretary of Health & Human Services (HHS), promulgate final regulations specifying the circumstances in which a special registration for telemedicine may be issued and the procedure for obtaining the registration. It has now been two full years since the SUPPORT Act was signed into law with no appreciable progress in moving forward a rulemaking process to implement this key telemedicine provision.

Given the opioid use crisis now heavily impacting the United States, the DEA’s delay is difficult to comprehend. In the six months since COVID-19 brought the nation to a standstill, the opioid epidemic has taken a sharp turn for the worse. More than 40 states have recorded increases in opioid-related deaths since the pandemic began. In Arkansas, the use of Narcan, an overdose reversing medication, has tripled. Officials in Jacksonville, FL have seen a 40 percent increase in overdose related emergency calls. In March alone, York County, PA recorded three times as many overdoses as usual.

The nationwide data is similarly alarming: drug overdoses increased 18 percent in March compared with last year, 29 percent in April, and 42 percent in May according to the Overdose Detection Mapping Application Program (ODMAP), a federal initiative that collects data from ambulance teams, hospitals, and police. Telemedicine is one of the key means of addressing this worsening crisis by expanding access to addiction treatment in underserved communities, rural areas, and communities of color.

Since the onset of the coronavirus epidemic Public Health Emergency (PHE), HHS has employed its authority under Section 1135 of the Social Security Act to waive a wide array of restrictions and limits on telemedicine imposed under Section 1834(m) of the Act. The DEA also recognized the immediate need
for expanded access to remote care during the pandemic and, in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA), exercised its regulatory authority to permit remote prescribing of controlled substances using telemedicine without a prior in-person exam, regardless of the patient’s location (if the prescribing is medically appropriate and the prescriber is DEA-registered). In particular, this has allowed buprenorphine/Suboxone initiation over telemedicine. While we appreciate these PHE-related changes, statute requires the implementation of a permanent regulation. The time for that regulation is long overdue.

It should be noted that – in numerous public appearances as well as in congressional testimony – HHS Secretary Alex Azar and U.S. Surgeon General Jerome Adams repeatedly refer to MAT as “the gold standard” of addiction treatment. Buprenorphine is a key part of the MAT armamentarium. It is an opioid medication used to treat opioid addiction in the privacy of a health care practitioner’s office or an outpatient clinic. Buprenorphine can be dispensed for take-home use by prescription filled in local pharmacies. These characteristics, in addition to buprenorphine’s pharmacological and safety profile, make it a preferred treatment option for patients addicted to opioids.

According to a Health Affairs blog authored by noted academic medical experts: “Telehealth had already been proven effective for managing patients who had already started buprenorphine treatment after an in-person visit, with multiple studies demonstrating similar retention and illicit opioid abstinence rates among patients managed by telehealth compared to in-person. Prior to COVID-19, the Department of Veterans Affairs successfully implemented telehealth buprenorphine management for veterans with OUD and has published a toolkit to support future expansion of telehealth buprenorphine programs.” Many healthcare providers across the United States have used telemedicine to expand access to MAT and report high clinician and patient satisfaction with telemedicine. In fact, the Centerstone Research Institute (CRI) even showed that telemedicine interventions have been 18 percent more effective at reducing past 30-day alcohol and tobacco use relative to face-to-face settings.

Given the worsening opioid overdose crisis, the undersigned organizations urge the DEA to move forward with the telemedicine special registration process required by federal law that will enable SAMHSA waivered clinicians, Community Mental Health Centers and addiction treatment facilities to prescribe MAT to patients with OUD employing telemedicine technology.

This important rulemaking also closely aligns with the October 5 Executive Order on Saving Lives Through Increased Support for Mental- and Behavioral-Health Needs and will disproportionately benefit patients with addiction disorders living in rural America and underserved urban areas.

Thank you for your attention to this important matter.

Sincerely,

Abbott House
Allergy & Asthma Network